Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PragmaTIL: ANV419 vs HD-IL-2 in TIL Therapy
NCT06630611Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jan 2025
- Primary completion
- Sep 2029
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ANV419 in melanoma, non-small cell lung cancer (NSCLC) and Cervical Cancer (CC) (2 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Predefined grade >=3 relevant adverse events related to interleukin use at 2 weeks and Patient Reported Outcomes CTCAE at 6 weeks. Started Jan 2025; status: recruiting.
02
Drugs
ANV419
03
Conditions
melanomanon-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06630611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630611.